ICU Medical (NASDAQ:ICUI) Stock Price Down 6.4% - Should You Sell?

Key Points

• ICU Medical's stock price fell by 6.4%, closing at $118.38, which is significantly below its previous closing price of $126.53 and saw a 48% volume decline from its average.
• Wall Street analysts have mixed ratings for the stock; Piper Sandler has set a target price of $153.00, while Raymond James has cut their target to $180.00, reflecting a consensus price target of $181.00.
• Despite the stock performance, ICU Medical reported a positive earnings per share of $2.10 for its last quarter, exceeding estimates, although revenue was down 8% compared to the same quarter last year.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report)'s share price was down 6.4% during trading on Thursday . The stock traded as low as $117.38 and last traded at $118.38. Approximately 140,864 shares changed hands during trading, a decline of 48% from the average daily volume of 268,876 shares. The stock had previously closed at $126.53.

Wall Street Analyst Weigh In

Several research analysts recently commented on ICUI shares. Piper Sandler lifted their target price on shares of ICU Medical from $145.00 to $153.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 10th. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday, September 5th. Finally, Raymond James Financial cut their target price on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, ICU Medical presently has an average rating of "Buy" and a consensus price target of $181.00.

ICU Medical Stock Performance

The business's 50-day simple moving average is $126.13 and its 200 day simple moving average is $133.06. The firm has a market cap of $2.91 billion, a P/E ratio of -77.50 and a beta of 0.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating the consensus estimate of $1.44 by $0.66. The company had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.ICU Medical's quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insider Activity

In other ICU Medical news, Director David C. Greenberg bought 1,200 shares of the company's stock in a transaction on Wednesday, August 27th. The shares were bought at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the acquisition, the director directly owned 7,960 shares in the company, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Vivek Jain bought 21,929 shares of the company's stock in a transaction on Thursday, August 14th. The shares were bought at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the transaction, the chief executive officer directly owned 130,149 shares in the company, valued at approximately $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cullen Frost Bankers Inc. purchased a new stake in ICU Medical in the 2nd quarter worth approximately $38,000. GAMMA Investing LLC raised its position in shares of ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 153 shares during the last quarter. Blue Trust Inc. lifted its stake in ICU Medical by 23.0% in the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock valued at $111,000 after buying an additional 150 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock valued at $128,000 after acquiring an additional 101 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of ICU Medical in the second quarter valued at approximately $177,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.